Fusion Antibodies News

Fusion Antibodies Supply Antibody Characterization

Humanized antibody Jf5 detects Aspergillus

  Towards translational ImmunoPET/MR imaging of invasive Pulmonary Aspergillosis: The Humanized Monoclonal Antibody JF5 detects Aspergillus Lung Infections in Vivo Objective Invasive pulmonary aspergillosis…
Fusion Antibodies Supply Antibody Characterization

Fusion Antibodies announces partnership with Protein Alternatives

Fusion Antibodies announces partnership with Protein Alternatives to develop world class humanized antibodies for therapeutic development Fusion Antibodies plc, a UK-based contract research organisation and Protein Alternatives,…
Fusion Antibodies Supply Antibody Characterization

Potential biomarkers for bladder and colon cancer

Non-phosphorylated and Phosphorylated Signal Transduction Peptide (STP) of Tissue Factor (TF) in Urine are Potential Biomarkers for Bladder and Colon Cancer. Objective Tissue factor (TF, CD142) is commonly associated with the initiation…
Fusion Antibodies Supply Antibody Characterization

Funding for Queen’s pancreatic cancer drug research in collaboration with Fusion Antibodies

Queen’s University Belfast researchers at the Centre for Cancer Research and Cell Biology (CCRCB) alongside Fusion Antibodies plc have secured a prestigious Medical Research Council (MRC) award to develop a new antibody drug for the treatment…
Fusion Antibodies Supply Antibody Characterization

Fusion Antibodies to double workforce with help from Invest NI

Fusion Antibodies has announced plans to create 28 new jobs. This recruitment drive, supported by Invest NI, will help Fusion Antibodies deliver its services to its growing international customer base. Invest NI has offered Fusion Antibodies…
Fusion Antibodies Supply Antibody Characterization

Phase 1 of Fusion Antibodies expansion project underway

We are delighted to showcase the progress of Phase 1 of our ambitious expansion project that is now well underway. As many of you will remember, in December 2017 Fusion Antibodies became one of only three companies in Northern Ireland…
Fusion Antibodies Supply Antibody Characterization

We have made the 2018 NI Dealmakers Awards shortlist!

Fusion Antibodies have been shortlisted for a category at the 2018 Northern Ireland Dealmakers Awards Fusion Antibodies are absolutely delighted to be shortlisted in the Deal of the Year (£2.5m - £10m) award category in the Insider…
Fusion Antibodies Supply Antibody Characterization

Coming in 2018!

We're delighted to announce that we have some new services launching in 2018! Developability and Manufacturability Services! We have developed a range of software analytics delving into the properties of antibodies. These…
Fusion Antibodies Supply Antibody Characterization

Fusion to become third Northern Irish Company listed on the London Stock Exchange

Fusion Antibodies to seek AIM IPO We are delighted to announce that we are seeking a listing on the AIM Market of the London Stock Exchange and has published its AIM Admission Document which will be available to view here. We propose…
Fusion Antibodies Supply Antibody Characterization

Fusion Antibodies are attending PEGS Europe

Fusion Antibodies are pleased to be attending PEGS Europe being held on 13-17th November in Lisbon, Portugal. PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Last year, in 2016, a record…
Fusion Antibodies Supply Antibody Characterization

Fusion Antibodies are attending BioFIT 2017

Fusion Antibodies are delighted to be attending BioFIT being held on 28-29th November in Strasbourg, France. BioFIT is the leading partnering event in Europe fortechnology transfer, academia-industry collaborations and early-stage…
Fusion Antibodies Supply Antibody Characterization

Meet us at BioJapan 2017

Fusion Antibodies are attending BioJapan 2017 Pharma Event Fusion Antibodies are pleased to be attending BioJapan 2017 being held on 11-13th October in Pacifico Yokohama, Japan. Chris Moriarty from the Fusion Team will be showcasing…